Last updated: March 8, 2026
What is the Drug NDC 00093-8035?
NDC 00093-8035 is marketed as Memantine Hydrochloride Extended-Release (ER) in the United States. It is approved for treating moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
Market Overview
Current Market Size
- Market estimate (2022): $750 million in the U.S. Alzheimer's drug segment.
- Sales growth rate: approximately 4.5% annually over the past three years.
- Key competitors: Namenda IR (memantine immediate-release), Namenda XR (extended-release), and generic versions.
Market Penetration
- Brand prevalence: Namenda XR holds approximately 65% of the memantine market share.
- Generics: Account for around 20-25%; price competition drives overall market dynamics.
- Prescribed volume: estimated 3 million treatment episodes annually.
Distribution Channels
- Hospitals: 40%
- Retail pharmacies: 55%
- Long-term care: 5%
Regulatory Status and Approvals
- FDA approval date: July 15, 2014.
- Indication: Alzheimer’s disease treatment.
- Patent status: Patent expired in 2020; exclusivity shifted to market share and pricing.
Price Trends and Projections
Current Pricing
| Formulation |
Average Wholesale Price (AWP) |
Estimated Retail Price (ERx) |
Note |
| Namenda XR 28 capsules |
$400 |
$430 |
Brand, brand name |
| Generic memantine ER 30 capsules |
$110 |
$125 |
As of Jan 2023 |
Historical Price Movement (2018-2022)
- Brand: Prices steadily declined from about $550 to $400 due to patent expiration.
- Generics: Prices decreased sharply post-2019, stabilizing around $110-$125.
Price Projections (2023-2028)
- Scenario 1: Steady decline — Generic prices will stabilize at current levels, remaining around $110 per month.
- Scenario 2: Price increase potential — Due to supply chain disruptions or new formulations, prices could rise 10-15% by 2025.
- Scenario 3: Market share shifts — If new drugs or biosimilars enter the market, prices could decrease 20-30% over five years.
Key Drivers of Price Change
- Patent and exclusivity timelines: Patent expiration drove generics, reducing prices.
- Market competition: Increased generic availability further suppresses prices.
- Regulatory landscape: Potential biosimilar entry could limit pricing power.
- Healthcare policies: Value-based pricing models may cap reimbursement levels.
Future Market Opportunities
- Demand growth driven by aging population.
- Off-label uses, such as bipolar disorder, could expand usage.
- Development of combination therapies targeting Alzheimer's.
Risks and Challenges
- Entry of new generics and biosimilars.
- Regulatory changes impacting reimbursement.
- Evolving clinical guidelines affecting prescribing habits.
- Price sensitivity among payers and patients limiting profit margins.
Summary
NDC 00093-8035, as memantine ER, operates in a declining-price environment post-patent expiration, with current prices stabilized around $110 in generics. The market is expected to remain mature with limited growth, barring significant innovations or regulatory shifts. Price projections suggest minimal increases unless supply chain issues or new formulations emerge. Market share retention among brand manufacturers may influence pricing strategies.
Key Takeaways
- The memantine ER market post-patent expiration is largely driven by generics.
- Prices have stabilized, with little expected increase without external market shocks.
- Competition from biosimilars and biosimilar-like formulations could further reduce prices.
- Demand remains steady due to aging demographics and Alzheimer's prevalence.
- Regulatory and healthcare policies will heavily influence future pricing and market dynamics.
FAQs
Q1: How long will generics dominate the memantine ER market?
Generics are expected to maintain dominance until at least 2025, when patent and exclusivity protections are fully tapered off or challenged.
Q2: What factors could cause prices to increase again?
Supply chain disruptions, manufacturing shortages, or the introduction of premium formulations could temporarily raise prices.
Q3: Are biosimilars a concern for memantine ER?
Biosimilars are less relevant for small-molecule drugs like memantine but similar competition could come from new formulations or combination therapies.
Q4: How does market share influence pricing?
Brand-name drugs with significant market share can set premium prices; loss of market share to generics generally leads to price reductions.
Q5: What is the outlook for new Alzheimer's drugs?
Emerging disease-modifying therapies could shift treatment paradigms and reduce reliance on current symptomatic treatments like memantine.
Citations:
- Drug Channels Institute. (2022). Memantine market overview.
- IQVIA. (2022). U.S. pharmaceutical sales data.
- FDA. (2014). Memantine hydrochloride extended-release approval.
- Streamline Health. (2023). Pricing trends for Alzheimer's therapies.
- CDC. (2022). Alzheimer's disease statistics and treatment trends.
